Published in Cell Mol Life Sci on July 10, 2014
Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments. Cancer Biol Ther (2016) 0.90
Molecular Testing of Brain Tumor. J Pathol Transl Med (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Identification of human brain tumour initiating cells. Nature (2004) 38.87
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 10.61
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
The glial nature of embryonic and adult neural stem cells. Annu Rev Neurosci (2009) 8.38
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol (2012) 8.16
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell (2004) 5.95
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron (2006) 5.34
Mosaic analysis with double markers in mice. Cell (2005) 5.32
Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science (2007) 5.23
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One (2009) 5.08
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell (2008) 5.06
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 4.78
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science (2012) 4.14
Corridors of migrating neurons in the human brain and their decline during infancy. Nature (2011) 4.12
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer (2006) 3.72
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science (2011) 3.52
Uniquely hominid features of adult human astrocytes. J Neurosci (2009) 3.49
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 3.46
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 2.98
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell (2012) 2.85
Glial specification in the vertebrate neural tube. Nat Rev Neurosci (2004) 2.75
Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell (2005) 2.74
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev (1998) 2.53
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) 2.53
Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci (2013) 2.46
Harnessing transposons for cancer gene discovery. Nat Rev Cancer (2010) 2.44
Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci (2006) 2.43
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab (2012) 2.20
A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15
The brain tumor microenvironment. Glia (2011) 2.13
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
The clinical implications of medulloblastoma subgroups. Nat Rev Neurol (2012) 2.12
Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene (2009) 1.96
Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
Phosphorylation state of Olig2 regulates proliferation of neural progenitors. Neuron (2011) 1.83
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet (2007) 1.80
Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A (2009) 1.79
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One (2011) 1.77
Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell (2011) 1.67
Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J (2009) 1.66
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
Mouse models of cancer. Annu Rev Pathol (2011) 1.59
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A (2004) 1.55
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res (2003) 1.46
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep (2013) 1.44
Deletion of Atoh1 disrupts Sonic Hedgehog signaling in the developing cerebellum and prevents medulloblastoma. Science (2009) 1.42
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS One (2011) 1.37
An RCAS-TVA-based approach to designer mouse models. Mamm Genome (2002) 1.36
Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res (2005) 1.35
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell (2012) 1.26
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. Nat Rev Neurosci (2012) 1.22
The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med (2012) 1.21
In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol (2012) 1.21
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92
Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma. J Clin Invest (2012) 1.12
Drm/Gremlin, a BMP antagonist, defines the interbud region during feather development. Int J Dev Biol (2004) 0.83